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In this contribution we present three case studies of physiologically based toxicokinetic (PBTK) modelling in regulatory risk
assessment. (1) Age-dependent lower enzyme expression in the newborn leads to bisphenol A (BPA) blood levels which are near
the levels of the tolerated daily intake (TDI) at the oral exposure as calculated by EFSA. (2) Dermal exposure of BPA by receipts,
car park tickets, and so forth, contribute to the exposure towards BPA. However, at the present levels of dermal exposure there is
no risk for the adult. (3) Dermal exposure towards coumarin via cosmetic products leads to external exposures of two-fold the
TDI. PBTK modeling helped to identify liver peak concentration as the metric for liver toxicity. After dermal exposure of twice the
TDI, the liver peak concentration was lower than that present after oral exposure with the TDI dose. In the presented cases, PBTK
modeling was useful to reach scientiﬁcally sound regulatory decisions.
1.Introduction
Physiologically based pharmaco-/toxico-kinetic (PBPK/
PBTK) modelling has a long history. The principle has been
introduced by Teorell as early as 1937 [1], but uptake and
further development has been slow. Beginning in the 60s,
pharmacokinetics became a constituent part in drug devel-
opment. In drug development a data-rich situation is given,
and studies in human beings can be performed without
ethical constraints. Hence, the kinetic paradigm developed
under those conditions was a top down approach, where
the structure of the kinetic model using compartmen-tal
models was determined by the statistically best ﬁt to the
data [2]. The kinetic parameters were estimated out of the
data. Without further information the parameters are hard
to interpret in a physiological context. Physiologically based
pharmacokinetic models have not been used in drug kinetics
to a great extent with the exception of modelling the fate of
anaesthetic drugs, where it has always been an interesting
approach [3, 4]. However, in the past twenty years there is
growing interest in this approach as a technique to support
deﬁning the dose which is intended to be given in the ﬁrst
studies in humans based on preclinical in vitro and in vivo
animal study results, the so-called ﬁrst dose in man [5].
Similarly in toxicology, interest is growing to apply this
approach to be used in risk assessment and recently an
internationally agreed document has been published on
the topic [6]. Here, the typical situation for a chemical is
characterized by existence of data in animal species but
only few, if any experimental data in humans. For risk
assessment or setting limit values (e.g., tolerated daily intake
(TDI), accepted daily intake (ADI), occupational exposure
limit (OEL)) the animal data have to be extrapolated to the
human physiology and in addition, also to the physiology of
the whole population including special subgroups. Typically,
default factors have been used. A factor of ten is seen to be
appropriate for the species diﬀerence between animal and
man (4 for toxicokinetic diﬀerences, 2.5 for toxicodynamic
diﬀerences) and a second factor of ten is applied for the
interspecies diﬀerences in the human population (3.2 for
toxicokinetic diﬀerences; 3.2 for toxicodynamic diﬀerences).
PBTK modelling may help to derive chemical-speciﬁc
assessment factors at least for the kinetic portion of the
chemical-speciﬁc assessment factors [7]. On the other hand,2 Journal of Toxicology
PBTK modelling may also help to better understand the
mode of action by identifying which kinetic metric is really
related to the toxic eﬀect, which is to be assessed [6].
In this contribution we present three case studies, where
we used PBTK modelling in order to perform a targeted risk
assessment. In two cases the uncertainty surrounding the use
of default values has been reduced. In one other case, the
PBTK modelling supported an outcome of the assessment
which is diﬀerent from the default approach and also helped
to identify the relevant toxicokinetic metric, thus oﬀering
some insight into the mode of action.
The modelling procedures of the examples have already
beenpublishedindetail.Theaimofthispaperistoshowhow
to embed PBTK modelling into a regulatory decision making
process.
2. Regulatory Problem, Methods, and Results:
CaseStudies
2.1. Case Study. Bisphenol A: Exposure in Newborns [8]
2.1.1. Regulatory Context. Bisphenol A (BPA) is a chemical
used for the production of epoxy resins and polycarbonate
plastics [9, 10]. Food in contact with plastic materials is
one source of human exposure. Feeding bottles from plastic
materials containing BPA have been identiﬁed to be a major
source for exposure to infants, including neonates, whereby
the oral intake by bottle fed infants was estimated to be
11μg/kg/day (worst-case estimate), several fold higher than
the oral exposure of adults by the European Food Safety
Agency (EFSA) [10]. The TDI (tolerated daily intake) is
50μg/kg/day derived from animal data [10]. It should be
mentioned that there is ongoing controversy about the TDI
being 50μg/kg/d as derived by EFSA and other regulatory
agencies. There are studies showing eﬀects of BPA below
50μg/kg/d, and some scientists are with the opinion that
these studies should be used as the basis to derive the TDI
[11]. We nevertheless used the regulatory TDI of 50μg/kg/d
for our modelling purposes. By deﬁnition the TDI is not
thought to be relevant for children below the age of 3
months. There is, however, no health-based limit value for
infants of this age available. Therefore, we used this value
for risk assessment. Although EFSA raised no concern for
newborns it remained open whether the impairment of
glucuronidation in the newborn with a capacity of less
than 10% of the adult [12] may result in increased internal
exposure. It should be noted that glucuronidation accounts
to 85–95.5% of the metabolic clearance in adults [13, 14].
2.1.2. Why PBTK Modelling? The exposure for the bottle-fed
neonate is at 1/5 of the TDI which has to be considered in
conjunction with the glucuronidation capacity of less that
10% of the normal value [12]. It is highly uncertain to
which extent a minor pathway (sulfation) contributing 15–
7.5% to the metabolic elimination in the adult [13, 14]m a y
compensate for the impaired metabolic capacity of the pre-
dominant pathway (glucuronidation). In order to reduce the
uncertainty, we modelled the internal exposure by a human
model for children of diﬀerent ages including newborns
and for adults in which we implemented both metabolic
pathways, and we compared the internal concentrations of
children at diﬀerent ages and the adult with the exposure by
a dose at the TDI.
2.1.3. What Has Been Done? Starting from a PBTK model
containing physiological data at diﬀerent ages [15], we
modiﬁed the input into the model from inhalation exposure
to oral exposure. The only elimination was by metabolism.
Glucuronidation was parametrized using published in vitro
data on Vmax and Km in hepatocytes of adult humans [16]
according to the formula given in [17]. Sulfation was mod-
elled according to the relative contribution to the metabolic
clearance [13]. For the newborns and infants, we searched
afterinformationontheexpressionoftherespectiveenzymes
in diﬀerent ages and used this information to adjust the
metabolic parameters. BPA undergoes glucuronidation by
the UDP-glucuronyltransferase UTG2B15 in man [18]. As
age-dependent expression of this enzyme is not available
we used data on UTG2B7 which is from the same UTG
family and has a high degree of homology with UTG2B15
[12]. The sulfation of BPA is mediated by SULT 1A1 which
is expressed already in utero at high levels similar to the
a d u l tl e v e l s[ 19]. Ginsberg and Rice [20] claimed that tissue
BPA concentrations may be higher due to deconjugation of
the metabolites in tissues. We calculated that given the low
partition coeﬃcient of the polar conjugated metabolites, less
than 10% of the concentration of the conjugated metabolites
will enter the tissues. Nishikawa et al. [21] demonstrated that
deglucuronidation is taking place, however, only to the small
extent of 4.4% in the fetus as calculated by Hengstler et al.
[22]. Thus, we are with the opinion that even if assuming
deconjugation of metabolites in tissues, this process can be
omitted from the model because it does not increase the
concentration by more than about 5%.
We modelled the concentration of the parent chemical
BPA in blood at a dose of 11μg/kg/day for newborn
(exposure assessment by [10]) and compared the steady
state concentration in blood of this dose with the steady
state concentration in blood in an adult, given the identical
dose of 11μg/kg/day. In the newborn, the concentration in
blood was 3.3 fold higher as compared to the adult (Table 1).
The steady state concentration in blood in the newborn of
the realistic worst case exposure scenario did not exceed
the adult steady state concentration in blood at a dose
of 50μg/kg/day which is the tolerated daily intake (TDI).
However, it was only 26.2% below this value (Table 1(a)).
We also modelled urinary excretion of the metabolites and
determined the relative contribution of the glucuronidation
versus the sulfation pathway. Table 1(b) shows that in the
newborn the sulfation pathway is predominant and that
with increasing age (and maturation of the glucuronide
pathway [12]) excretion by sulfation pathway decreases and
glucuronidation becomes the predominant pathway.
2.1.4. Sources of Uncertainty. Our model has several limita-
tions. We scaled Vmax from in vitro the in vivo situation
using a published formula which is the result of a consensus
[17]. Partition coeﬃcients were taken from experimentalJournal of Toxicology 3
Table 1: BPA steady state concentration in blood after oral exposure by 11μg/kg/day in bottle fed newborns. The steady state concentration
(SSC) is compared to a steady state concentration in an adult exposed to 11μg/kg/day and to the 50μg/kg/day on the oral route. It can be
seen that the steady state concentration in the newborn is three-fold higher than in the adult due to the fact that the metabolism of BPA by
glucuronidationisimpairedinthenewborn.However,theSSCinthenewborndoesnotexceedtheSSCofanoraldoseof50μg/kg/d.Theoral
dose of 50μg/kg/d equals the tolerated daily intake derived from animal studies. It is thought to be a level without adversely inﬂuencing the
health calculated for the population older than 3 months. The SSC of 50μg/kg/d has been simulated with the model parameters of an adult.
Relative contribution of the two pathways in the metabolism of BPA in relation to age (and related to age extent of impaired glucuronide
conjugation). 85% of a dose of BPA is metabolized to the glucuronide conjugate to and the remaining 15% to the sulfate conjugate in the
adult. The enzyme which mediates the conjugation to BPA-glucuronide (uridine diphosphate-glucuronosyltransferase 2B15, UTG 2B15) is
expressed at birth to only 10% of the adult level. The expression levels reach adult levels by the age of 1.5 years. The relative percentage of the
glucuronidation pathway depends on the expression level of UTG 2B15. In the newborn only 36% of the absorbed dose is metabolized via
glucuronidation, whereas 64% of the absorbed dose is sulfated.
(a)
Oral exposure
(μg/kg/day)
Steady state
concentration
(SSC) (ng/mL)
Percentage of
TDI SSC
SSC newborn/SSC
adult at 11μg/kg/day
Newborn (bottle-fed) 11 (EFSA, 2006) 0.096 73.8 3.3
Adult 11 (hypothetical) 0.029 22.3 —
Adult 50 (TDI) 0.13 100 —
(b)
Sulfate conjugate
(percentage of the absorbed dose)
Glucuronide conjugate
(percentage of the absorbed dose)
Newborn 64% 36%
3 months 31% 69%
6 months 18% 82%
1.5 year 15% 85%
Adult 15% 85%
data in rats because data in humans were not available. The
rate of absorption was estimated using the time course of
urinary excretion of the conjugated metabolite which is an
imprecise estimate. Finally, we assumed perfusion-limited
distribution into the tissues. Concerning the age-dependent
expression of UTG 2B15, we assumed that the expression
pattern is the same as UTG 2B7. The data needed for valida-
tion of the model are not at hand as in experimental studies
with known exposure the parent compound BPA was below
the level of detection (overview in [22]). The remaining
uncertainty is given by the unknown ontogeny of UTG2B15
and by the imprecise estimate of the rate of absorption.
However, the simulation results were not contradictory to
published simulation results, where parameter estimation
has been performed diﬀerently [22]. Therefore, we do have
some conﬁdence in the results (Figure 1).
2.1.5. Conclusion. The PBTK modelling results conﬁrmed
the risk assessment which has been performed on rather
qualitative estimates than on quantiﬁcation. However,
because internal exposure expressed as the concentration
in blood has been simulated for the external exposure at
11μg/kg/d in the newborn and for the exposure at the TDI
for an adult, it can be seen that the oral exposure with
11μg/kg/day exhausted the TDI to 74%. Hence, it can be
stated that, at oral exposure as calculated by EFSA [10],
no risk is present unless exposures not accounted for so
far, for example, by dermal route at high doses, would
become known. As far as it is known today, there is no
dermal exposure in the newborn and infant whereas dermal
exposure in the adult has been found (see case study no. 2).
It is a belief that one pathway of elimination can “com-
pensate”forasecondpathwaywhenimpaired[23].However,
asshownhere,althoughinthenewbornthesulfationexceeds
glucuronidation, the increased percentage eliminated via the
sulfatepathway does not fully“compensate”forthe impaired
glucuronidation pathwaywhichis indicated bythediﬀerence
in blood levels between newborns and adults (Table 1(a)).
This ﬁnding is of general importance for risk assessment
in newborns and other populations at risk with impaired
metabolic and renal elimination function.
2.2. Case Study. Bisphenol A: Dermal Exposure [24]
2.2.1. Regulatory Context. The oral route of exposure has
beenassumedtobethemainsourceofexposureinconsumer
risk assessment of BPA [22, 24]. However, in the past several
authors reported blood concentrations of BPA which were
far higher than could be explained by the estimated exposure
on the oral route up to now [25, 26] (citing the authors
with the lowest and the highest concentrations in blood).
Concerns have always been raised that the present risk
assessment considering only the oral route of exposure is
overlooking exposures by other routes which have to be
considered to assess the true risk from BPA exposures. In
2010, several reports have been published reporting that BPA4 Journal of Toxicology
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Figure 1: BPA: simulation results oral versus dermal route. Humans are exposed towards BPA on the oral and on the dermal routes.
is present in thermal printing papers and products made
fromthermalprintingpapersuchasreceipts,carparktickets,
queue tickets, ATM receipts, lottery slips, and plane, train,
and bus tickets in the percentage range (0.8–3.2%) [27–29].
Furthermore, BPA is taken up on the surface of the ﬁngers
when BPA-containing paper is touched, and it is getting into
the skin [27]. In [27], a daily dermal exposure of 71μg/day
is estimated for the consumer, corresponding to roughly 1μg
BPA/kg/day on this route.
The question is whether the additional external dermal
exposure which is in the range of the external oral exposure
would explain the high blood concentrations which in turn
would raise concern. The TDI of 50μg/kg/day for BPA
is derived from an oral study, the target organ being the
liver. In the standard risk assessment the procedure is to
correct the external dermal dose for the percentage of dermal
absorption relative to the oral absorption. This corrected
dose is then added to the oral dose. If the sum is below the
TDI,noconcernwillberaised.Asdermalexposureisanewly
detected route of exposure, we applied a reverse reference
scenario and estimated the dermal exposure doses necessary
to yield the reported blood concentrations adding to the
maximum external oral exposure estimated by FAO/WHO
[30]. We did this in order to clarify whether the exposureJournal of Toxicology 5
by the dermal route can explain the high concentrations
measured by some authors in blood, and whether this
constitutes a concern (Table 2(b)).
2.2.2. Why PBTK Modelling? The described approach for
route-to-route extrapolation is in line with the standard
procedure for risk assessment. However, there are two
questions. First, as the liver is the target tissue, to what extent
is the liver exposed by the dermal route. Second question was
to which extent is the exposure of organs other than the liver
increased by dermal exposure. Given the fact that BPA has a
high ﬁrst pass in the liver, it is anticipated that the route of
exposure is an important determinant for the concentration
in organs other than the liver. A PBTK analysis was the way
to tackle the problem.
2.2.3. What Has Been Done?
(1) Dermal Modelling: Risk Assessment. We simulated the
BPA concentration time proﬁle in blood, liver, and kidney
using a PBTK human model with oral route of exposure
already published [8] (see above) and added a dermal path-
way of exposure. The concentration time proﬁle in kidney
was simulated because minimal-to-mild nephropathy was
related to doses above 50mg/kg/day given orally in a study
[31]. The extent of dermal absorption of BPA has been
reported by several authors with varying values, that is, 10%
[9], 13% [32], 46% [33], and 60% [27]. Based on the data of
[27], we assumed that dermal absorption could be described
by a diﬀusion process of ﬁrst order and estimated a half-life
of 8 hours, whereas oral absorption half-life was assumed to
be15minasinthestudyof[34]themaximumconcentration
in the urine occurred at roughly 1h. We performed the
simulations assuming that the extent of absorption is 10%,
13%, 46%, or 60%. Here, we report only the results obtained
with 60% dermal absorption. We compared the output of
simulations of a dermal dose of 71μg (0.97μg/kg/day), given
as a single dose, of an identical oral dose of 0.97μg/kg/day,
given in three equal portions, an oral dose of 4.2μg/kg/d
(FAO/WHO estimate [30]), given in three equal portions,
and of 50μg/kg/day (the TDI), given in three equal portions.
The results showed that dermal exposure leads to lower peak
concentration in the target organ liver and to higher peak
concentrations in blood and kidney as compared to the oral
exposure. The AUC in blood and kidney is higher after
dermal exposure as compared to dosing on the oral route.
AUC in the liver is determined by the extent of absorption
(Table 2(a)). With the dose of 50μg/kg/day (TDI level) by
the oral route AUC in the liver is 96 fold higher. Cmax in
the liver depends on the extent of absorption, the proportion
of cardiac output which is going through the liver (22.5%)
and also from the absorption half-life with slow absorption
leading to low peak concentrations in the liver and fast
absorption leading to high peak concentrations in the liver.
Cmax in the liver was 700 fold higher after 50μg/kg/day (TDI
level) on the oral route than after 0.97μg/kg/day by the
dermal route.
(2)AssessmentofDermalExposureNecessarytoYieldReported
Concentrations in Blood. In addition, in order to clar-
ify whether blood concentrations as measured by several
authors were in the range of exposures measured so far we
ﬁnally calculated the dermal dose, which its intake would be
necessarytoreachthereportedconcentrationsof0.33ng/mL
[25]a n d5 . 9n g / m L[ 26] when combined with the maximum
oral intake of 4.2μg/kg/day as estimated by [30]. As can
be seen in Table 1(b), the dermal doses of 9.4μg/kg/day
and of 211.8μg/kg/day are necessary to yield concentration
of 0.33ng/mL and of 5.9ng/mL from combined oral (as
estimated by [18]) and dermal exposure, respectively.
The modeling results are in line with the physiology of
dermal versus oral absorption. When absorbed through the
skin, BPA ﬁrst enters the venous blood. The venous blood
is drained into the upper main vein, passing the right
ventricle and the lungs and entering the left atrium and left
ventricle. By this process the amount absorbed is mixed in
the bloodstream coming from other organs. From the left
ventricle, BPA is distributed via arterial blood throughout
the body. In contrast, after oral administration BPA is
directly delivered to the liver via the portal vein after passing
through the intestinal wall. Taking all aspects together, after
absorption through the skin the blood in the portal vein has
a lower concentration as compared to the oral route because
of the physiology. Furthermore, dermal absorption of BPA is
much slower than the oral absorption which is the general
rule. Thus, Cmax in the liver is several fold lower after dermal
as compared to the oral administration.
2.2.4. Source of Uncertainty. Our model has the limitations
as mentioned for the BPA model above. In addition, the
parameter for the rate and extent of dermal absorption as
taken from the publication of Biedermann et al. [27]a r e
approximations. The data needed to resolve this uncertainty
are not easily obtained as an experimental in vivo study in
humans would be necessary to be performed. Given the level
of detection, we do not expect that this data need will be
solved in the near future. Even in the most recent study [35]
BPA concentrations were below the detection limit of 1.3nM
as analysed by CDC. Therefore, this very important point is
a remaining source of uncertainty. Nevertheless, as we made
worst-case assumptions the simulation results are of value to
inform risk assessment.
2.2.5. Conclusion. For the risk assessment, concerning liver
toxicity we cannot determine what the relevant metric is.
There are no data which would allow deciding whether
toxicity is related to AUC or to Cmax.
For regulatory decision making, the PBTK modelling and
simulation results were helpful to identify a relevant route
of exposure for the consumer which results in higher blood
concentration than after the identical dose on the oral route.
From the modeling results we can decide that the worst-case
exposure estimate for consumers on the dermal route is safe.
Even if higher blood concentration of a dose given by
the dermal route is taken into consideration, the doses to
reach the concentrations reported by most of the authors in6 Journal of Toxicology
Table 2: BPA: Simulation results comparing of oral and dermal exposure. Results are given as Cmax (pg/g) and AUC (pg/g × h) in blood,
liver, and kidney after dermal (extent of absorption 60% of the dose), and oral (extent of absorption 90% of the dose) administration. The
external oral doses are identical with the external dermal dose (0.97μg/kg/d), a dose estimated by FAO/WHO (4.2μg / k g / d )a st h eu p pe rl ev e l
estimate and a dose at the tolerated daily intake (TDI) (50μg/kg/d). BPA undergoes ﬁrst pass in the liver. The ﬁrst pass in the liver produces
a lower concentration in the systemic circulation (Cmax and AUC in blood) compared to values after the dermal administration despite
identical doses and a lower extent of absorption through skin as compared to the oral absorption. In contrast, Cmax and AUC in the liver
are higher after oral as compared to the dermal exposure. Dermal dose (μg/kg/d) of BPA which corresponds to the concentration diﬀerence
between blood concentrations published by Sajiki et al., 1999 [25] and by Padmanabhan et al., 2008 [26] and the estimated oral dose by
FAO/WHO, 2010. The blood concentration of BPA in a person who has ingested BPA at the upper level of oral exposure (4.2μg/kg/d) as
calculated by FAO/WHO is 70.6pg/mL. Sajiki et al., 1999 [25] has measured a mean blood concentration of 330pg/mL and Padmanabhan
et al., 2008 [26], a mean blood concentration of 5900pg/mL. We calculated the diﬀerence of the blood concentrations measured by Sajiki
et al. and by Padmanabhan et al. [25, 26] and the modelled blood concentration caused by an oral dose of 4.2μg/kg/d. We then modelled
the dermal dose which would be necessary to produce the concentration corresponding to the diﬀerence between measured and modelled
concentration. It can be seen that this dose (9.4 and 211.8μg/kg/d, resp.) is 10 to 200 fold higher than the experimentally measured dose of
0.97μg/kg/d [27].
(a)
Blood∗ Liver Kidney
Route of
administration Dose (μg/kg/d) Extent of absorption
(percentage of dose)
Absorption
half-life (hrs)
Cmax
(pg/g)
AUC
(pg/g × h)
Cmax
(pg/g)
AUC
(pg/g × h)
Cmax
(pg/g)
AUC
(pg/g × h)
Dermal
oral
0.97∗∗ 60 8 26.7 416.7 3.2 50.3 36.1 563.3
0.97∗∗ 90 0.25 16.3 64.0 44.7 93.3 22.0 86.3
4.2∗∗ 90 0.25 70.6 277.1 193.5 403.9 95.3 373.7
50 (TDI)∗∗ 90 0.25 841.0 3293.3 2300 4800 1140 4433
∗Blood concentration in the systemic circulation, not in the portal vein. In case of the oral route of administration, concentration in the portal vein is
higher than concentration in the systemic circulation.
∗∗Dermal dose given at once, whereas the oral doses are given in three divided portions.
(b)
Blood concentration
(mean; pg/mL)
Blood concentration of the oral
dose of 4.2μg/kg/d (pg/mL)
Diﬀerence of the concentrations
(pg/mL)
Dermal dose corresponding to the
concentration diﬀerence
(μg/kg/d)
330 [25] 70.6 259.4 9.4
5900 [26] 70.6 5,829.4 211.8
the literature are orders of magnitude higher than estimated,
based on measurements. In this respect it should be noted
that allstudies in which high blood concentrations measured
were uncontrolled, in particular uncontrolled in terms of
the material of collecting blood, previous treatment of
patients (e.g., intensive care or Cesarean section). It has
been demonstrated that in intensive care the exposure
towards BPA can be extremely high [36]. Hence, the high
BPA concentrations measured by some authors might be
explained by exposure via the intravenous route (medical
devices) or by contamination when taking blood. Hence,
we are with the opinion that the credibility of measured
concentrations by [25, 26] is highly uncertain.
2.3. Case Study. Coumarin: Dermal Exposure [37]
2.3.1. Regulatory Context. Coumarin risk assessment has
been performed because coumarin exposure by the oral
route became a matter of concern. In addition to the
oral route, humans may be exposed to coumarin by the
dermal route because coumarin is used in several cosmetic
products. In 2004 in an EFSA report, the risk from oral
exposure by coumarin has been assessed. In this report,
exposure to coumarin from cosmetic products has been
mentioned being twice as high as the exposure via food [38].
Two German surveys provided detailed information on the
contents of coumarin in cosmetic products [39, 40]. In the
EU, there are generally agreed procedures [41–45]o nh o wt o
calculate external exposure via cosmetic products based on
the contents of cosmetics using default assumption on the
use pattern and use frequency. Using the German data and
the EU-procedures, the German Federal Institute for Risk
Assessment (BfR) calculated the external coumarin exposure
for a consumer by the dermal route by cosmetic products. A
correction factor for skin absorption was introduced based
on experimental data for route-to-route extrapolation [46,
47]. Under the assumption of a worst-case scenario the
exposure level was 0.14mg/kg bw/day which exceeds the TDI
of coumarin at the level of 0.1mg/kg bw/day and raised
concern [48]. It has to be mentioned that the TDI was
derived from oral studies, and that the target organ was the
liver showing dose-dependent signs of toxicity.
2.3.2. Why PBTK Modelling? The risk assessment procedure
is in line with the standard approach for route-to-route
extrapolation.Inthecaseofcoumarin,however,thequestion
was whether it is appropriate to use an oral TDI as a limitJournal of Toxicology 7
value to assess the risk resulting from dermal exposure or
whether speciﬁc considerations apply for a substance with
high ﬁrst-pass elimination via hepatic metabolism such as
coumarin. As there was some uncertainty concerning this
questiontheriskassessmentrequiredfurtherveriﬁcationand
substantiation. The way to solve the problem has been to
perform a PBTK analysis in which it turned out that the
crucial point was to identify the relevant dose metric for the
toxicological endpoint which is liver toxicity.
2.3.3. What Has Been Done?
(1) PBTK Modelling of the Target Concentrations in Humans.
In humans, the kinetics of the parent compound coumarin
has been studied following oral or intravenous administra-
tion of the compound [49–52]. Furthermore, in vivo and in
vitro results on dermal absorption were available [44, 45].
Metabolismofcoumarinwasstudiedininvitroexperiments,
and human Km and Vmax values have been published [53].
The available data did allow us to use them for a human
P B T Km o d e lw i t ho r a la n dd e r m a lr o u t eo fe x p o s u r e . I nt h e
human model, we modelled absorption of 100% [50]a n d
similar absorption half-lives (20min for the oral and 30min
for the dermal absorption) in accordance with experimental
results [46, 47, 50]. The dermal exposure to coumarin
at a level of 0.1mg/kg bw (i.e., oral TDI) resulted in a
lower simulated peak concentration in the liver (Cmax-hep =
1.2μg/kg liver) compared to the situation when the identical
dose was given by the oral route (Cmax-hep = 3.6μg/kg liver).
The diﬀerence between oral Cmax-hep and dermal Cmax-hep
increases when the rate of dermal absorption decreases.
For example, in particular circumstances depending on the
cosmetic preparation, as has experimentally been shown, the
dermal absorption half-life is 960min. With an extent of
absorption of 100% through the skin, and this absorption
half-life the peak concentration in the liver is 0.06μg/kg liver.
TheAUCintheliverinallcases(oralanddermal)isthesame
(see Table 3).
The route-dependent diﬀerence of AUC in blood is
explained by the fact that after oral administration the
absorbed dose is undergoing ﬁrst pass in the liver before
entering the systemic circulation, whereas after dermal
exposure the absorbed dose is undergoing ﬁrst pass in
the skin to a negligible extent (which we did not include
into our model) before entering the systemic circulation.
Hence, in this case, the systemic availability, also called bio-
availability, is diﬀerent from the extent of absorption. The
same explanation holds true for the diﬀerence in Cmax in
blood.The question was whether diﬀering Cmax values in the
liver depending on the route of administration are relevant
for the risk assessment.
(2) PBTK Modelling of Rat Data. We identiﬁed 11 oral rat
studies in the literature with information on doses and
duration of the study and also information on feeding the
doses (dietary or gavage). The information on dose (between
2.3mg/kg/day and 535mg/kg/day) and duration of exposure
(between 4 weeks and 104 weeks) was used in a rat PBTK
model to simulate concentration-time proﬁles in blood and
in the liver. Rat metabolism data (Km and Vmax)w e r e
available from published source [53]. The resulting 31 values
for the Cmax in the liver and AUC in the liver ranged from 0.6
to 197.1μg/g and from 529 to 590 227μg/g × h.
(3) Assessing the Relationship between Liver Toxicity and Cmax
Versus AUC in the Liver. In the 11 studies we identiﬁed 31
hepatotoxic responses described as the main toxicological
endpoint. In each study the severity of the hepatotoxicity
increased with increasing dose. We used the description of
the hepatotoxic eﬀect to grade the response into a ﬁve-point
grading scale in which zero is no eﬀect, and four is massive
liver toxicity.
In order to solve the question whether the relevant
toxicokinetic metric is Cmax or AUC in the target organ
liver, we combined graded hepatic toxicity responses with
Cmax- and AUC-values in the liver as resulting from PBTK
simulations in a rat model.
We performed a graphical analysis to identify whether
liver toxicity was related to AUChep or to Cmax-hep.T h e
analysis revealed that the severity grade of hepatotoxicity
increases systematically with increasing Cmax-hep, whereas for
AUChep no systematic increase of the severity grade with
increasing AUChep could be seen (Figures 2(a) and 2(b)).
2.3.4. Source of Uncertainty. Our model has the following
limitations. We scaled Vmax f r o mi nv i t r ot oi nv i v os i t u a t i o n
using a published formula which is the result of a consensus
[17]. Partition coeﬃcients were calculated values and not
experimentally obtained [5]. Although the rate and extent of
absorption by the oral route and by the dermal route were
taken from experimental data in humans, the data on the
dermal route was estimated using the time course of urinary
excretion of the conjugated metabolite which is an imprecise
estimate. Finally, we assumed, perfusion limited distribution
into the tissues which determines the time course in the
tissue of interest, that is, the liver. The data needed to resolve
this uncertainty are not easily obtained as an experimental in
vivo study in humans would be necessary to be performed,
in which the parent compound has to be measured. There-
fore, there is remaining uncertainty. Nevertheless, when
we compared the simulated oral data with the published
experimental data in humans the simulation predicted the
time course fairly well [37].
2.3.5. Conclusion. The ﬁndings indicate that in rats
coumarin-mediated liver toxicity is related to the peak
liver concentration rather than to AUC in the liver. Hence,
standard procedures for route-to-route extrapolation are
not appropriate as they can only adjust for the amount
entering the body and not for the peak concentration in the
relevant organ. In conclusion, the PBTK modelling resulted
in a diﬀerent outcome of the risk assessment compared to
the conventional approach based on external exposure or
dose. As the peak concentration in the liver after dermal
exposureisbelowthepeakliverconcentrationresultingfrom
oral exposure with a dose corresponding to the TDI, and8 Journal of Toxicology
Table 3: Comparison of the peak concentrations and AUC in blood and liver after oral and dermal exposure towards coumarin. Cmax and
AUC of coumarin were modelled in liver and in blood after 0.1mg/kg by the oral route (extent of absorption 100%; half-life of absorption
20min) and dermal route (extent of absorption 100%; half-life of absorption 30min and 960min dependent on the cosmetic preparation).
It can be seen that the AUC in the liver is identical because the amount absorbed and reaching the liver is the same. However, because of
diﬀerences in the absorption half-life Cmax in the liver diﬀers. In blood, AUC is diﬀerent due to ﬁrst pass in the liver. Even if the extent of
absorption is identical the amount of coumarin reaching the systemic circulation after oral exposure is lower than after dermal exposure.
Cmax in blood depends on the rate of absorption, expressed as half-life. If half-life of dermal absorption is similar to the oral absorption
(30min versus 20min), Cmax is higher after dermal exposure (due to ﬁrst pass in the liver after oral exposure and no ﬁrst pass in the skin). If
half-life of dermal absorption is prolonged as compared to the oral half-life of absorption (960min versus 20min). Cmax is lower. Thus, it is
not only the extent but also the rate of absorption, which matters in comparing oral and dermal exposure.
Dose (mg/kg) Route of
administration
Dose fraction
which is
absorbed
Absorption
half-life (min)
Cmax liver
(μg/kg)
AUC liver
(μg/kg × h)
Cmax blood
(μg/kg)
AUC blood
(μg/kg × h)
0.1 Oral 1.0 20 3.6 1.8 3.1 32
0.1 Dermal 1.0 30 1.2 1.8 51 77
0.1 Dermal 1.0 960 0.06 1.8 2.7 77
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Figure 2: Exploration of which toxicokinetic metric is toxicodynamically relevant. Severity grade of liver toxicity (points) in relation to (a)
the peak concentration in the liver (μg/g liver tissue) for coumarin in rat. (b) AUC in the liver (μg/g × h) for coumarin in rat. A toxicokinetic
modelhasbeenconstructedfortherat,and Cmax and AUCweresimulated with dosesand durationof exposuretaken frompublished studies
(n = 11). The toxicological endpoint in the studies was liver toxicity the degree of which diﬀered, and we graded the toxicity in a scale from
0t o4 .Cmax in the liver (liver peak concentration) was better correlated to liver toxicity than AUC in the liver indicating that it Cmax in the
liver is the toxicologically relevant toxicokinetic metric.
peak concentration is the relevant metric, it can be stated
that there is no health concern by the current exposure by
cosmetic products.
As a general comment, it can be concluded that in route-
to-route extrapolation for chemicals with high ﬁrst-pass
elimination via hepatic metabolism special attention has to
be given not to underestimate the possible risk in organs
other than the liver as tissue exposure (AUC) can be higher.
PBTK Can help to estimate critical dose metrics (e.g., AUC
and Cmax) for various tissues within the body as a function
of exposure route and intensity. While the example for
coumarin shows that dermal exposures lead to lower Cmax of
parent compound in liver as compared to an oral exposure,
forcompoundsthathavetoxicitiesrelatedtoAUCintheliver
orothertargetorgans,dermalmayleadtohighercriticaldose
metrics. PBPK modelling helps risk assessors address these
important toxicology and risk assessment issues.
3. General Conclusion
Risk assessment of chemicals in general and also targeted
risk assessments are demanding processes. In particular, for
targeted risk assessment in a regulatory environment ques-
tions have to be deﬁnitively answered. Risk assessment needs
several extrapolation steps which are based on assumptions
which are inherently surrounded with uncertainty. Often
default assumptions have to be applied because of lack of
data. However, even in cases where more data is available
the preferred regulatory procedure is to apply default
assumptions. In the last decade, PBTK modelling has been
advocated as a means to support risk assessment and to
reduce the uncertainty [6]. There is increasing awareness
in regulatory decision making on the usefulness of this
approach. The following examples show that BPPK mod-
elling has found regulatory acceptance in the interspeciesJournal of Toxicology 9
extrapolation from animal to man, namely, vinyl acetate,
2-butoxyethanol, propylene methyl glycol (EU Existing
Chemicals Program), formaldehyde, 2-butoxyethanol (UK
Health and Safety Executive), tetrachloroethylene, styrene,
diethylhexlyphthalate (Health Canada), dichloromethane,
ethylene glycol monobutyl ether, and vinyl chloride (US
EPA (IRIS)) [54]. Cadmium is one example where human
variability has been quantiﬁed, and a chemical speciﬁc
factor was used instead of the default factor [54]. The
cases we present in this contribution deal with scenarios,
where modelling was done in human models. In the ﬁrst
case, the purpose was to quantify intraspecies variability for
a substance, where two metabolic pathways with diﬀerent
maturation states in the newborn are present. In cases two
and three, we elucidated the pitfalls of the conventional
approach for oral to dermal extrapolation for substances
with high ﬁrst-pass elimination via hepatic metabolism. The
three case studies demonstrate that the extrapolation using
conventional approaches may lead to regulatory decisions
which bear the possibility to overlook problems or to
overstate the risk. In the three cases, PBTK modelling helped
inform risk assessment. The answers to the questions require
a physiologically appropriate structural model, knowledge
on the physiological changes by life stages, and kinetics
of absorption by various routes of exposure. By using
modelling approaches the uncertainty is reduced. In this
contribution we do not deal with uncertainty and variability
inPBTKmodelsasaddressedbyothersforexample,[55,56].
However, we applied the lessons learned [54], and we hope
that the case studies are convincing for regulators, the public,
and also for scientists.
References
[1] T.Teorell,“Kineticsofdistributionofsubstancesadministered
to body,” Archives Internationales de Pharmacodynamie et de
Therapie, vol. 57, pp. 205–240, 1937.
[2] S. G. Dahl, L. Aarons, U. Gundert-Remy et al., “Incor-
porating physiological and biochemical mechanisms into
pharmacokinetic-pharmacodynamic models: a conceptual
framework,” Basic and Clinical Pharmacology and Toxicology,
vol. 106, no. 1, pp. 2–12, 2010.
[3] W. W. Mapleton, “Chest gas-exchange theory using an electri-
cal analogue,” Journal of Applied Physiology, vol. 19, pp. 1193–
1199, 1964.
[4] M. N. Ashman, W. B. Blesser, and R. M. Epstein, “A nonlinear
model for the uptake and distribution of halothane in man,”
Anesthesiology, vol. 33, no. 4, pp. 419–429, 1970.
[5] P. Poulin and F. P. Theil, “Prediction of pharmacokinetics
prior to in vivo studies—II. Generic physiologically based
pharmacokinetic models of drug disposition,” Journal of
Pharmaceutical Sciences, vol. 91, no. 5, pp. 1358–1370, 2002.
[6] IPCS/WHO, “Characterization and Application of Physiolog-
ically Based Pharmacokinetic models in Risk Assessment,”
2010.
[7] IPCS/WHO, “Chemical speciﬁc adjustment factors for inter-
species diﬀerences and intraspecies variability: guidance doc-
ument for use of data in dose/concentration response assess-
ment,” 2005.
[8] H. Mielke and U. Gundert-Remy, “Bisphenol A levels in blood
depend on age and exposure,” Toxicology Letters, vol. 190, no.
1, pp. 32–40, 2009.
[9] European Union (EU), “Risk Assessment Report 4,4 -
isopropylidenediphenol (bisphenol-A) CAS No: 80-05-7
EINECS No: 201-245-8 Series,” 3rd Priority List Volume 37,
Oﬃce for Oﬃcial Publications of the European Communities,
2003.
[10] EFSA (European Food Safety Authority), “Opinion of the
Scientiﬁc Panel on Food Additives, Flavourings, Processing
Aids and Materials in Contact with Food (AFC) related to 2,2-
bis(4-hydroxyphenyl)propane; Question number EFSA-Q-
2005-100,” 2011, http://www.efsa.europa.eu/en/efsajournal/
pub/428.htm.
[11] F. S. vom Saal and C. Hughes, “An extensive new literature
concerning low-dose eﬀects of bisphenol A shows the need for
a new risk assessment,” Environmental Health Perspectives, vol.
113, no. 8, pp. 926–933, 2005.
[12] M. J. Zaya, R. N. Hines, and J. C. Stevens, “Epirubicin glu-
curonidation and UGT2B7 developmental expression,” Drug
Metabolism and Disposition, vol. 34, no. 12, pp. 2097–2101,
2006.
[13] X.Ye, Z.Kuklenyik, L. L. Needham, and A.M.Calafat, “Quan-
tiﬁcation of urinary conjugates of bisphenol A, 2,5-
dichlorophenol, and 2-hydroxy-4-methoxybenzophenone in
humans by online solid phase extraction-high performance
liquid chromatography-tandem mass spectrometry,” Analyti-
cal and Bioanalytical Chemistry, vol. 383, no. 4, pp. 638–644,
2005.
[14] H.Kurebayashi,K.Okudaira,andY.Ohno,“Speciesdiﬀerence
of metabolic clearance of bisphenol A using cryopreserved
hepatocytes from rats, monkeys and humans,” Toxicology
Letters, vol. 198, no. 2, pp. 210–215, 2010.
[15] K. Abraham, H. Mielke, W. Huisinga, and U. Gundert-
Remy, “Elevated internal exposure of children in simulated
acute inhalation of volatile organic compounds: eﬀects of
concentration and duration,” Archives of Toxicology, vol. 79,
no. 2, pp. 63–73, 2005.
[16] R. K. Kuester and I. G. Sipes, “Prediction of metabolic clear-
ance of bisphenol A (4,4 -dihydroxy-2,2- diphenylpropane)
using cryopreserved human hepatocytes,” Drug Metabolism
and Disposition, vol. 35, no. 10, pp. 1910–1915, 2007.
[17] Z. E. Barter, M. K. Bayliss, P. H. Beaune et al., “Scaling factors
for the extrapolation of in vivo metabolic drug clearance
from in vitro data: reaching a consensus on values of human
microsomal protein and hepatocellularity per gram of liver,”
Current Drug Metabolism, vol. 8, no. 1, pp. 33–45, 2007.
[18] N. Hanioka, T. Naito, and S. Narimatsu, “Human UDP-
glucuronosyltransferase isoforms involved in bisphenol A
glucuronidation,”Chemosphere,vol.74,no.1,pp.33–36,2008.
[19] Z. Duanmu, A. Weckle, S. B. Koukouritaki et al., “Develop-
mental expression of aryl, estrogen, and hydroxysteroid sul-
fotransferases in pre- and postnatal human liver,” Journal of
Pharmacology and Experimental Therapeutics, vol. 316, no. 3,
pp. 1310–1317, 2006.
[20] G. Ginsberg and D. C. Rice, “Does rapid metabolism ensure
negligible risk from bisphenol A?” Environmental Health Per-
spectives, vol. 117, no. 11, pp. 1639–1643, 2009.
[21] M. Nishikawa, H. Iwano, R. Yanagisawa, N. Koike, H. Inoue,
and H. Yokota, “Placental transfer of conjugated bisphenol A
and subsequent reactivation in the rat fetus,” Environmental
Health Perspectives, vol. 118, no. 9, pp. 1196–1203, 2010.10 Journal of Toxicology
[22] J. G. Hengstler, H. Foth, T. Gebel et al., “Cutting edge
topics of the current controversy on BPA,” Critical Reviews in
Toxicology, vol. 41, pp. 263–291, 2011.
[23] “EFSA toxicokinetics of bisphenol A,” The EFSA Journal, vol.
759, pp. 1–10, 2008.
[24] H. Mielke, F. Partosch, and U. Gundert-Remy, “The contribu-
tion of dermal exposure to the internal exposure of bisphenol
Ai nm a n , ”Toxicology Letters, vol. 204, no. 2-3, pp. 190–198,
2011.
[25] J. Sajiki, K. Takahashi, and J. Yonekubo, “Sensitive method
for the determination of bisphenol-A in serum using two
systems of high-performance liquid chromatography,” Journal
of Chromatography B, vol. 736, no. 1-2, pp. 255–261, 1999.
[26] V. Padmanabhan, K. Siefert, S. Ransom et al., “Maternal
bisphenol-A levels at delivery: a looming problem?” Journal
of Perinatology, vol. 28, no. 4, pp. 258–263, 2008.
[27] S. Biedermann, P. Tschudin, and K. Grob, “Transfer of
bisphenolAfromthermalprinterpapertotheskin,”Analytical
andBioanalyticalChemistry,vol.398,no.1,pp.571–576,2010.
[28] T. Mendum, E. Stoler, H. van Benschoten, and J. C. Warner,
“Concentration of bisphenol A in thermal paper,” Green
Chemistry Letters and Reviews, vol. 4, no. 1, pp. 81–86, 2011.
[29] T. ¨ Ostberg and E. Noaksson, “Bisfenol A in svenska kvitton,”
Analysresultat. Institutet f¨ or till¨ amoa gr¨ on kemi. J¨ amtlands
l¨ ans Landsting, 2010.
[30] FAO/WHO Joint FAO/WHO, “Expert Meeting to Review
Toxicological and Health Aspects of Bisphenol A,” Summary
Report, 2010.
[31] R. W. Tyl, C. B. Myers, M. C. Marr et al., “Three-generation
reproductive toxicity study of dietary bisphenol A in CD
Sprague-Dawley rats,” Toxicological Sciences,v o l .6 8 ,n o .1 ,p p .
121–146, 2002.
[32] T. J. Mørck, G. Sorda, N. Bechi et al., “Placental transport and
in vitro eﬀects of Bisphenol A,” Reproductive Toxicology, vol.
30, no. 1, pp. 131–137, 2010.
[33] D. Zalko, C. Jacques, H. Duplan, S. Bruel, and E. Perdu,
“Viable skin eﬃciently absorbs and metabolizes bisphenol A,”
Chemosphere, vol. 82, no. 3, pp. 424–430, 2011.
[34] T. Tsukioka, J. Terasawa, S. Sato, Y. Hatayama, T. Makino,
and H. Nakazawa, “Development of analytical method for
determining trace amounts of BPA in urine samples and
estimation of exposure to BPA,” Journal of Environmental
Chemistry, vol. 14, pp. 57–63, 2004.
[35] J.G.Teeguarden,A.M.Calafat,X.Yeetal.,“Twenty-fourhour
human urine and serum proﬁles of bisphenol A during high-
dietary exposure,” Toxicological Sciences, vol. 123, no. 1, pp.
48–57, 2011.
[36] A. M. Calafat, J. Weuve, X. Ye et al., “Exposure to bisphenol A
and other phenols in neonatal intensive care unit premature
infants,” Environmental Health Perspectives, vol. 117, no. 4, pp.
639–644, 2009.
[37] H. Mielke, K. Abraham, M. G¨ otz et al., “Physiologically
based toxicokinetic modelling as a tool to assess target
organ toxicity in route-to-route extrapolation—the case of
coumarin,” Toxicology Letters, vol. 202, no. 2, pp. 100–110,
2011.
[38] EFSA (European Food Safety Authority), “Opinion of the
scientiﬁc panel on food additives, ﬂavourings, processing aids
and materials in contact with food (AFC) on a request from
the commission related to Coumarin,” The EFSA Journal, vol.
104, pp. 1–136, 2004.
[39] W. Umbach, K o s m e t i kv o nK o p fb i sF u s s , Wiley-VCH, Wein-
heim, Germany, 3rd edition, 2004.
[40] “Inspectorate of the German States,” Internal Report, 2005.
[41] Scientiﬁc Committee on Cosmetic Products and Non-
Food Products intended for Consumers (SCCNFP), “Opin-
ion concerning 6-Acetyl-1,1,2,4,4,7-Hexamethyltetryltetralin
(AHTN) SCCNFP/0609/02,” 2002.
[42] Scientiﬁc Committee on Cosmetic Products and Non-Food
Products intended for Consumers (SCCNFP), “Opinion con-
cerning Hexahydrohexamethyl-cyclopenta (γ)-2-benzopyran
(HHCB) SCCNFP/0610/02,” 2002.
[43] Scientiﬁc Committee on Cosmetic Products and Non-Food
Products intended for Consumers (SCCNFP), “Note for
Guidance for testing of cosmetic ingredients and their safety
evaluation,” 5th revision, 2003.
[44] Scientiﬁc Committee on Cosmetic Products and Non-Food
Products intended for Consumers (SCCNFP), 2004, “Opinion
concerning musk xylene and musk keton, SCCNFP/0817/04.
Scientiﬁc Committee on Consumer Products (SCCP). Note
for Guidance for testing of cosmetic ingredients and their
safety evaluation,” 6th revision, 2006.
[45] Scientiﬁc Committee on Food (SCF), Opinion on coumarin
( a constituent of natural ﬂavouring source materials limited
by Annex II of ﬂavourings directive 88/388/EEC), expressed
on 16 December 1994. Reports of the Scientiﬁc Committee
on Food (36th series). European Commission, Directorate
General Industry. Luxembourg, 1997.
[ 4 6 ]S .A .J .B e c k l e y - K a r t e y ,S .A .M .H o t c h k i s s ,a n dM .C a p e l ,
“Comparative in vitro skin absorption and metabolism of
coumarin (1,2-benzopyrone) in human, rat, and mouse,” Tox-
icology and Applied Pharmacology, vol. 145, no. 1, pp. 34–42,
1997.
[47] R. A. Ford, D. R. Hawkins, B. C. Mayo, and A. M. Api, “The in
vivo dermal absorption and metabolism of [4-14C]coumarin
by rats and by human volunteers under simulated conditions
of use in fragrances,” Food and Chemical Toxicology, vol. 39,
no. 2, pp. 153–162, 2001.
[48] BfR (Bundesinstitut fuer Risikobewertung). Kosmetika
k¨ onnenwesentlich zurGesamtaufnahme vonCumarinbeitra-
gen. (BfR Nr. 049/2007), 2007, http://www.bfr.bund.de/cm/
206/kosmetika koennen wesentlich zur gesamtaufnahme
von cumarin beitragen.pdf.
[ 4 9 ]W .A .R i t s c h e l ,K .A .H o ﬀmann, H. S. Tan, and P. R. Sanders,
“Pharmacokinetics of coumarin upon i.v. administration in
man,” Drug Research, vol. 26, no. 7, pp. 1382–1387, 1976.
[50] W. A. Ritschel, M. E. Brady, and H. S.I. Tan, “Pharma-
cokinetics of coumarin and its 7-hydroxy-metabolites upon
intravenous and peroral administration of coumarin in man,”
European Journal of Clinical Pharmacology,v o l .1 2 ,n o .6 ,p p .
457–461, 1977.
[51] W. A. Ritschel, M. E. Brady, and H. S. I. Tan, “First-pass
eﬀect of coumarin in man,” International Journal of Clinical
Pharmacology Therapy and Toxicology, vol. 17, no. 3, pp. 99–
103, 1979.
[52] W. A. Ritschel and S. A. Hussain, “Transdermal absorption
and topical availability of coumarin,” Methods & Findings in
Experimental & Clinical Pharmacology, vol. 10, pp. 165–169,
1988.
[53] I. M. C. M. Rietjens, M. G. Boersma, M. Zaleska, and A.
Punt, “Diﬀerences in simulated liver concentrations of toxic
coumarinmetabolitesinratsanddiﬀerenthumanpopulations
evaluated through physiologically based biokinetic (PBBK)
modeling,” Toxicology in Vitro, vol. 22, no. 8, pp. 1890–1901,
2008.
[54] G. Loizou, M. Spendiﬀ,H .A .B a r t o ne ta l . ,“ D e v e l o p m e n t
of good modelling practice for physiologically based pharma-
cokinetic models for use in risk assessment: the ﬁrst steps,”Journal of Toxicology 11
Regulatory Toxicology and Pharmacology,v o l .5 0 ,n o .3 ,p p .
400–411, 2008.
[55] H. A. Barton, W. A. Chiu, R. Woodrow Setzer et al., “Char-
acterizing uncertainty and variability in physiologically based
pharmacokinetic models: state of the science and needs for
research and implementation,” Toxicological Sciences, vol. 99,
no. 2, pp. 395–402, 2007.
[56] A. Y. Weiße and W. Huisinga, “Error-controlled global sen-
sitivity analysis of ordinary diﬀerential equations,” Journal of
Computational Physics, vol. 230, no. 17, pp. 6824–6842, 2011.